Diabetes patients benefit from computational analysis

Posted In: Diseases | Medical Technology | Technology | Computer Technology | Modeling | Biotechnology | Computers & Peripherals

Tuesday, June 30, 2009

Loading...
Researchers from North Carolina State Univ. and Mayo Clinic have developed a computer model that medical doctors can use to determine the best time to begin using statin therapy in diabetes patients to help prevent heart disease and stroke.

"The research is significant because patients with diabetes are at high risk for cardiovascular disease and statins are the single most commonly used treatment for patients at risk of heart disease and/or stroke," says Dr. Brian Denton, "and this model can help determine the best course of action for individual patients based on their risk of developing cardiovascular disease." Denton is an assistant professor in NC State's Edward P. Fitts Department of Industrial & Systems Engineering and lead author of the study.

Statins are a key component of current cardiovascular medical treatment guidelines, Denton says. They lower cholesterol levels and may significantly reduce the risk of heart attack and stroke, particularly in patients that are considered to be at high risk.

The researchers developed a new mathematical model that examines various possible treatment policies to see how they influence short-term and long-term health outcomes for patients. The model shows how people are affected by diabetes, and how their health changes over time as the disease advances and patients age.

The new model incorporates patient-specific data. An established risk model calculates each patient's probability of heart attack and stroke based on risk factors, such as their cholesterol, blood pressure, etc. This overall risk "score" is used to weigh the medical advantages of beginning statin therapy against the financial cost of the statins.

Overall, by accounting for the progression of diabetes, the patient's specific risk score and the cost-benefit analysis, the new model may help patients and doctors decide on the optimal time to begin statin therapy.

Denton says the new model has not yet been put into practice, but that the research team plans to develop a pilot to put the tool into the hands of medical professionals.

The research, "Optimizing the Start Time of Statin Therapy for Patients with Diabetes," was funded in part by the Agency for Healthcare Research and Quality and the National Science Foundation, and was published earlier this month in the journal Medical Decision Making. The research was co-authored by Denton from NC State; Nilay D. Shah, Sandra C. Bryant and Steven A. Smith of the Mayo Clinic College of Medicine; and University of Pittsburgh graduate student Murat Kurt.

Original Release

Study Abstract

SOURCE: North Carolina State Univ.

JOIN THE DISCUSSION
Rate Article:  Average 0 out of 5
Register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

New To Market

more

P2i showcases liquid repellent nano-coating for hearing aids
P2i showcases liquid repellent nano-coating for hearing aids

At the AudiologyNOW! 2010 show in San Diego next month, UK-based coatings company P2i will display their relatively new Aridion liquid-repellant nano-coating. Designed for exposure to humidity or sweat, the polymer layer is applied by a pulsed ion gas process that lower’s the hearing aid’s surface energy, coaxing water away from delicate components.

Submersible FlowCAM catches particle images and data in-situ and real-time

Fluid Imaging Technologies recently introduced its Submersible FlowCAM particle and cell imaging and analysis system at Ocean Sciences 2010 in Portland, Ore. The remote sensing platform can be used for continuous, unattended monitoring tethered to research vessels or autonomous submersibles.

Tools & Technology

more

Benchtop NMR analyzer
Benchtop NMR analyzer

Oxford Instruments America, Inc.’s Magnetic Resonance Group released the second generation of its MQC analyzers.

Software solution for microarray image analysis

BioDiscovery Inc. released ImaGene 9.0 for microarray image analysis. The new features include improved memory performance for the latest high density arrays, streamlined processing pipeline focused on image quantification and intensity extraction, and new modular design with options to add modules for analysis of gene/miRNA expression or CGH data.

Advertisement

Advertisement